title: iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo .
abstract: Invariant natural killer T (iNKT) cells comprise a lineage of CD1d-restricted glycolipid-reactive T lymphocytes with important roles in host immunity to cancer. iNKT cells indirectly participate in antitumor responses by inducing dendritic cell maturation and producing cytokines that promote tumor clearance by CD8+ T and NK cells. Although iNKT cells thereby act as potent cellular adjuvants, it is less clear whether they directly control the growth of tumors. To gain insights into the direct contribution of iNKT cells to tumor immune surveillance, we developed in vitro and in vivo systems to selectively examine the antitumor activity of iNKT cells in the absence of other cytolytic effectors. Using the EL4 T-lymphoma cell line as a model, we found that iNKT cells exert robust and specific lysis of tumor cells in vitro in a manner that is differentially induced by iNKT cell agonists of varying T-cell receptor (TCR) affinities, such as OCH, α-galactosyl ceramide, and PBS44. In vitro blockade of CD1d-mediated lipid antigen presentation, disruption of TCR signaling, or loss of perforin expression significantly reduce iNKT cell killing. Consistent with these findings, iNKT cell reconstitution of T, B, and NK cell–deficient mice slows EL4 growth in vivo via TCR-CD1d and perforin-dependent mechanisms. Together, these observations establish that iNKT cells are sufficient to control the growth of T lymphoma in vitro and in vivo. They also suggest that the induction of iNKT cell cytotoxic responses in situ might serve as a more effective strategy to prevent and/or treat CD1d+ cancers, such as T lymphoma.
authors.forename: Hamid
authors.initials: H
authors.lastname: Bassiri
authors.forename: Rupali
authors.initials: R
authors.lastname: Das
authors.forename: Peng
authors.initials: P
authors.lastname: Guan
authors.forename: David M
authors.initials: DM
authors.lastname: Barrett
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Brennan
authors.forename: Pinaki P
authors.initials: PP
authors.lastname: Banerjee
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Wiener
authors.forename: Jordan S
authors.initials: JS
authors.lastname: Orange
authors.forename: Michael B
authors.initials: MB
authors.lastname: Brenner
authors.forename: Stephan A
authors.initials: SA
authors.lastname: Grupp
authors.forename: Kim E
authors.initials: KE
authors.lastname: Nichols
mesh_terms: D000818:Animals; D055610:Antigens, CD1d / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000276:immunology; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D004195:Disease Models, Animal; D015870:Gene Expression; D006017:Glycolipids / Q000276:immunology; D016399:Lymphoma, T-Cell / Q000235:genetics / Q000276:immunology* / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D051379:Mice; D018345:Mice, Knockout; D055611:Natural Killer T-Cells / Q000276:immunology* / Q000378:metabolism; D054353:Perforin / Q000235:genetics / Q000378:metabolism; D011485:Protein Binding; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism; D015398:Signal Transduction; D047368:Tumor Burden / Q000235:genetics / Q000276:immunology
chemical_list: D055610:Antigens, CD1d; D000951:Antigens, Neoplasm; D006017:Glycolipids; D011948:Receptors, Antigen, T-Cell; D054353:Perforin